Ghanaian pharmacist and regulator Delese Mimi Darko has been named in the 2026 TIMEHealth 100 list under the Titan category, in recognition of her leadership in establishing a continental medicines regulatory body for Africa.
The citation commends her role in building the African Medicines Agency, a specialised agency of the African Uniondesigned to harmonise the approval and oversight of medicines and vaccines across member states.
From Accra to Addis Ababa
Darko previously served as Chief Executive Officer of Ghana’s Food and Drugs Authority, where she oversaw regulatory reforms and emergency authorisations during the COVID-19 pandemic.
At the height of the crisis, she observed stark differences in how regions processed vaccine approvals. In Europe, a single authorisation by the European Medicines Agency enabled coordinated rollout across multiple countries. In Africa, by contrast, individual national authorities conducted separate reviews, often with limited resources and varying timelines.
Public health experts say that fragmentation contributed to delays in access and highlighted the need for regulatory convergence across the continent.
In 2025, Darko was appointed as the first Director-General of the African Medicines Agency, becoming the inaugural head of the newly operational body. The agency is intended to provide scientific opinions, coordinate regulatory decisions and support member states in ensuring that medicines circulating on the continent meet international standards of safety, efficacy and quality.
Continental ambition
The African Medicines Agency was conceived to reduce duplication of regulatory work, strengthen pharmacovigilance systems and curb the circulation of substandard and falsified medicines. It also aims to support Africa’s growing pharmaceutical manufacturing ambitions.
According to information published on the TIMEHealth platform, around 30 of the African Union’s 55 member states have so far signed on to the agency. Full continental participation remains the long-term objective.
Health policy analysts note that while the agency does not replace national regulators, it is expected to provide a coordinated framework that countries can rely on in approving medical products, particularly during public health emergencies.
For Ghana, Darko’s recognition reflects the country’s increasing visibility in global health governance. The Food and Drugs Authority has in recent years attained international recognition for regulatory maturity, positioning it as one of the leading medicines authorities in sub-Saharan Africa.
Global spotlight, local implications
Being named in the TIMEHealth 100 list places international attention on Africa’s regulatory reform agenda at a time when the continent is seeking greater self-reliance in vaccine and medicine production.
The challenge ahead for the African Medicines Agency will be translating political commitment into sustainable financing, technical capacity and cross-border coordination.
As Africa continues to face both infectious disease threats and a rising burden of non-communicable diseases, the effectiveness of a unified regulatory system could play a critical role in ensuring faster, safer access to essential medical products for more than a billion people.
Darko’s inclusion on the list signals growing global recognition that regulatory leadership is central to health security — not only during pandemics, but in building resilient health systems for the future.
